Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Alkermes revenue
Alkermes's revenue is $1.6 billion.
What is Alkermes's revenue?
- Alkermes's revenue growth from 2011 to 2024 is 734.56%.
- Alkermes has 1,200 employees, and the revenue per employee ratio is $1,298,026.
- Alkermes's peak quarterly revenue was $617.4M in 2023(q2).
- Alkermes peak revenue was $1.7B in 2023.
- Alkermes annual revenue for 2023 was 1.7B, 49.61% growth from 2022.
- Alkermes annual revenue for 2024 was 1.6B, -6.36% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Alkermes historical revenue
Alkermes's peak revenue was $1.7B in 2023. The peak quarterly revenue was $617.4M in 2023(q2).
Alkermes's revenue increased from $186.6m in 2011 to $1.6B currently. That's a 734.56% change in annual revenue.
Alkermes annual revenue
Alkermes annual revenue over time
| Fiscal year / year | Alkermes revenue |
|---|---|
| 2011 | $186.6M |
| 2012 | $390.0M |
| 2013 | $575.5M |
| 2014 | $618.8M |
| 2015 | $628.3M |
| 2016 | $745.7M |
| 2017 | $903.4M |
| 2018 | $1.1B |
| 2019 | $1.2B |
| 2020 | $1.0B |
| 2021 | $1.2B |
| 2022 | $1.1B |
| 2023 | $1.7B |
| 2024 | $1.6B |
How accurately did Alkermes' revenue projections match actual performance?
Alkermes annual growth
Alkermes saw the greatest revenue growth in 2012, when revenue increased by 108.95%.
Alkermes had the lowest revenue growth in 2020, when revenue changed by -11.29%.
Alkermes annual growth rate over time
| Year | Alkermes growth |
|---|---|
| 2012 | 109%↑ |
| 2013 | 48%↑ |
| 2014 | 8%↑ |
| 2015 | 2%↑ |
| 2016 | 19%↑ |
| 2017 | 21%↑ |
| 2018 | 21%↑ |
| 2019 | 7%↑ |
| 2020 | -11%↓ |
| 2021 | 13%↑ |
| 2022 | -5%↓ |
| 2023 | 50%↑ |
| 2024 | -6%↓ |
Alkermes quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Alkermes quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | $152.2M | $125.6M | $130.5M |
| 2013 | $163.4M | $138.6M | $139.8M | $133.7M |
| 2014 | $130.2M | $153.4M | $160.0M | $175.2M |
| 2015 | $161.2M | $151.4M | $152.7M | $163.1M |
| 2016 | $156.8M | $195.2M | $180.2M | $213.5M |
| 2017 | $191.8M | $218.8M | $217.4M | $275.4M |
| 2018 | $225.2M | $304.6M | $248.7M | $315.8M |
| 2019 | $223.1M | $279.9M | $255.2M | $412.7M |
| 2020 | $246.2M | $247.5M | $265.0M | $280.0M |
| 2021 | $251.4M | $303.7M | $294.1M | $324.5M |
| 2022 | $278.5M | $276.2M | $252.4M | $304.7M |
| 2023 | $287.6M | $617.4M | $380.9M | $377.5M |
| 2024 | $350.4M | $399.1M | $378.1M | $430.0M |
Alkermes jobs nearby
Do you work at Alkermes?
Is Alkermes transparent about its revenue structure?
Alkermes financial information
| CEO | Richard F. Pops |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 1,200 |
| Date Founded | 1987 |
| Headquarters | Waltham, Massachusetts |
| Number of Locations | 3 |
| Revenue | $1.6B |
| Net Income | -$158,267,000 |
| Gross Proft | $1.3B (2024) |
| EBITDA | $419.9M (2024) |
| PE Ratio | 20.46 |
| Tax Rate | 0.2% |
| Market Capitalization | $7.5B |
| Total Assets | $1,963,978,000 |
| Ticker | ALKS |
Alkermes jobs you might like
Alkermes financing
Alkermes received early financing of $250.0M on 2014-01-13.
| Series | Round size | Date |
|---|---|---|
| Post-IPO Equity - Alkermes | 11/2017 | |
| Post-IPO Equity - Alkermes | $250M | 01/2014 |
Alkermes investors
| Investors | Security type |
|---|---|
| Primecap Management | Post-IPO Equity - Alkermes |
| Invesco | Post-IPO Equity - Alkermes |
Alkermes competitors
Alkermes's top competitor, Sanofi Genzyme, earned an annual revenue of $4.6B.
Alkermes's smallest competitor is T2 Biosystems with revenue of $7.2M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Novavax | $76,541 | $682.2M | 791 | 5 |
| MannKind | $78,771 | $10.0M | 233 | 47 |
| Acambis | $75,102 | $10.0M | 350 | - |
| Althea Technologies | $45,270 | $7.3M | 100 | - |
| LifeScan | $56,476 | $1.5B | 2,400 | 25 |
| CIMA Labs | $74,201 | $8.5M | 120 | 15 |
| XOMA | $52,959 | $28.5M | 11 | - |
| Emergent BioSolutions | $77,521 | $1.6B | 1,834 | 11 |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| 454 Life Sciences | $54,620 | $19.4M | 100 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Alkermes highest paying jobs
Zippia gives an in-depth look into the details of Alkermes, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alkermes. The employee data is based on information from people who have self-reported their past or current employments at Alkermes. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alkermes. The data presented on this page does not represent the view of Alkermes and its employees or that of Zippia.
Alkermes may also be known as or be related to ALKERMES INC, Alkermes, Alkermes Controlled Therapeutics Inc, Alkermes Inc and Alkermes plc.